Skip to main content

Table 1 Comparison of model selection and fit of all models considered in the analysis for viral suppression at 48 weeks as an outcome

From: Comparing the use of aggregate data and various methods of integrating individual patient data to network meta-analysis and its application to first-line ART

Analyses Model DIC pD Deviance Between study heterogeneity prop3 prop4
AgD NMA – Unadjusted Fixed 186.69 68.38 118.31 0.07 (0.003, 0.199) 2/116 2/116
AgD NMA meta-regression – CD4 Fixed 187.26 69.25 118.01 0.082 (0.006, 0.211) 2/116 2/116
AgD NMA meta-regression – HIV RNA Fixed 188.79 69.38 119.41 0.07 (0.005, 0.194) 2/116 2/116
AgD NMA meta-regression – Male Fixed 188.98 69.42 119.56 0.07 (0.003, 0.195) 2/116 2/116
Two-stage AgD NMA – CD4 + HIV RNA + Male Fixed 189.14 68.37 120.77 0.072 (0.003, 0.204) 2/116 2/116
Two-stage AgD NMA – CD4 + Male Fixed 188.21 68.38 119.83 0.076 (0.003, 0.208) 2/116 2/116
Two-stage AgD NMA – CD4 + HIV RNA Fixed 193.10 68.42 124.68 0.088 (0.005, 0.228) 3/116 2/116
Two-stage AgD NMA – HIV RNA + Male Fixed 190.15 68.44 121.71 0.078 (0.005, 0.215) 2/116 2/116
Two-stage AgD NMA – HIV RNA Fixed 191.23 67.67 123.56 0.087 (0.005, 0.225) 3/116 2/116
Two-stage AgD NMA – CD4 Fixed 189.06 67.70 121.36 0.082 (0.005, 0.222) 2/116 2/116
Two-stage AgD NMA – Male Random 205.19 82.51 122.68 0.167 (0.017, 0.306) 4/116 3/116
One-stage IPD-AgD NMA – unadjusted Fixed 185.11 68.45 116.66 0.072 (0.003, 0.2) 2/116 2/116
One-stage IPD-AgD NMA – CD4 + HIV RNA + Male Fixed 188.65 71.41 117.24 0.066 (0.003, 0.204) 2/116 2/116
One-stage IPD-AgD NMA – CD4 + Male Fixed 188.35 70.21 118.14 0.074 (0.002, 0.206) 2/116 2/116
One-stage IPD-AgD NMA – CD4 + HIV RNA Fixed 187.19 70.54 116.65 0.073 (0.004, 0.204) 2/116 2/116
One-stage IPD-AgD NMA – HIV RNA + Male Fixed 188.90 70.58 118.32 0.074 (0.004, 0.207) 2/116 2/116
One-stage IPD-AgD NMA – CD4 Fixed 186.82 69.31 117.51 0.067 (0.001, 0.206) 2/116 2/116
One-stage IPD-AgD NMA – HIV RNA Fixed 187.76 69.36 118.4 0.074 (0.003, 0.203) 2/116 2/116
One-stage IPD-AgD NMA – Male Fixed 186.40 69.48 116.92 0.068 (0.004, 0.199) 2/116 2/116
Two-stage empirical-priors approach– CD4 + HIV RNA + Male Fixed 198.56 77.47 121.09 0.104 (0.012, 0.244) 2/116 2/116
Two-stage empirical-priors – CD4 + Male Fixed 197.69 74.18 123.51 0.108 (0.006, 0.253) 2/116 2/116
Two-stage empirical-priors – CD4 + HIV RNA Fixed 192.22 74.75 117.47 0.071 (0.003, 0.221) 2/116 2/116
Two-stage empirical-priors – HIV RNA + Male Fixed 195.30 74.40 120.90 0.091 (0.004, 0.23) 2/116 2/116
Two-stage empirical-priors – CD4 Fixed 191.28 71.49 119.79 0.082 (0.008, 0.215) 2/116 2/116
Two-stage empirical-priors – HIV RNA Fixed 193.05 71.16 121.89 0.09 (0.004, 0.228) 3/116 2/116
Two-stage empirical-priors – Male Fixed 188.59 71.81 116.78 0.075 (0.004, 0.208) 2/116 2/116
HMR IPD-AgD NMA – CD4 Fixed 185.25 70.07 115.18 0.061 (0.005, 0.181) 2/116 2/116
HMR IPD-AgD NMA – HIV RNA Fixed 187.21 70.45 116.76 0.066 (0.001, 0.192) 2/116 2/116
HMR IPD-AgD NMA – Male Fixed 186.34 70.44 115.90 0.072 (0.003, 0.197) 2/116 2/116
  1. AgD Aggregate data, IPD Individual patient data, NMA Network meta-analysis, DIC Deviance information criterion, pD Effective number of parameters, prop3 Proportion of observations above deviance2 + leverage = 3, prop4 Proportion of observations above deviance2 + leverage = 4. Between-study heterogeneity obtained through the random-effects model, not the fixed-effect model if it was selected